Twitter Facebook LinkedIn

Heat Biologics, Inc. Heat Biologics, Inc.

  • Home
  • About
    • Management Team
    • Board of Directors
    • Scientific Advisory Board
    • Pelican Therapeutics
    • Heat Biologics Mask
  • Technology
    • gp96 Platform
    • Pelican’s PTX-35 Co-stimulatory Antibody
  • Product Pipeline
    • Overview
    • HS-110
    • HS-130
    • COVID-19 Vaccine
    • PTX-35
    • Expanded Access
    • Scientific Publications
  • Investors
    • Overview
    • News / Events
    • Company Information
    • Financial Information
    • Stock Data
    • SEC Filings
    • Corporate Governance
    • Corporate Presentation
  • News & Media
    • News Releases
    • Events
  • Careers
  • Contact

News Releases

News & Media

News & Media

  • News Releases
  • Events

Heat Biologics Announces Publication of Additional Preclinical COVID-19 Vaccine Results

Jan 27, 2021

Heat Biologics CEO to Participate in a Fireside Chat at the B. Riley Securities Oncology Investor Conference on Jan 21, 2021

Jan 20, 2021

Heat Biologics Commences Manufacturing Process for ZVX-60

Jan 19, 2021

Heat Biologics Promotes William L. Ostrander to Chief Financial Officer

Jan 11, 2021

Heat Biologics to Present at the H.C. Wainwright Virtual BioConnect 2021 Conference

Jan 8, 2021

Heat Biologics Announces Completion of ZVX-60 Vaccine Cell Line for COVID-19

Dec 16, 2020

Heat Biologics Provides Business Update

Dec 10, 2020

Heat Biologics Provides Third Quarter 2020 Business Update

Nov 9, 2020

Heat Biologics Issued Additional Patent on gp96 Combination Platform Therapy with T-cell Co-Stimulator

Oct 7, 2020

Heat Biologics CEO to Participate in Virtual Panel: "New Approaches to COVID-19: Hidden Breakthroughs," on Thursday, September 10th

Sep 9, 2020
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • ...25
© 2021 Heat Biologics, Inc. All Rights Reserved.
Privacy Policy Disclaimer Sitemap LinkedIn